Zobrazeno 1 - 10
of 20
pro vyhledávání: '"J. M. Sabio"'
Autor:
N. Navarrete-Navarrete, J. Escobar Sevilla, M. Toribio García, F. Urbano, J. M. Sabio, J. Jiménez-Alonso
Publikováno v:
Case Reports in Infectious Diseases, Vol 2015 (2015)
We present the case of a patient with an infection by Nocardia which manifested itself with monocular endophthalmitis. Nocardia infection is not common and ocular involvement is one of the most uncommon presentations. In these cases it is very import
Externí odkaz:
https://doaj.org/article/31a400d097f2484b94d41cedbd0e18ca
Autor:
J. M. Sabio, Carlos Garcia-de los Ríos, Marta Medina-Casado, María del Mar Del Águila-García, Rafael Cáliz-Cáliz, Antonio Díaz-Chamorro
Publikováno v:
Rheumatology International. 43:253-263
Cardiovascular disease (CVD) is a main cause of death in patients with systemic lupus erythematous (SLE). Algorithms for cardiovascular risk stratification in general population underestimate the risk for CVD in SLE. Our study aimed to determine whet
Publikováno v:
Lupus. 15:54-57
Autor:
E. Ros-Díe, Juan Jiménez-Alonso, C. Hidalgo-Tenorio, P. J. P. Linares, L. M. Salmerón, J. M. Sabio-Sánchez
Publikováno v:
Clinical Rheumatology. 27:115-117
Magic syndrome is a very uncommon disease, and vascular involvement is exceptional; only one case has been reported in the literature associated to a true aortic aneurysm. The treatment of aneurysms recommended in these patients is based on isolated
Autor:
J, Jiménez-Alonso, J A, Vargas-Hitos, N, Navarrete-Navarrete, M, Zamora-Pasadas, S, Aguilar-Huergo, L, Jáimez, J M, Sabio
Publikováno v:
Revista clinica espanola. 213(9)
A series of measures in the management of patients with systemic lupus erythematosus (SLE) which usually are not found in the lupus guidelines are discussed. In the lupus patient who has been well-controlled in the long term, the dose of hydroxychlor
Autor:
R, Cervera, I, Rúa-Figueroa, A, Gil-Aguado, J M, Sabio, L, Pallarés, L J, Hernández-Pastor, M, Iglesias
Publikováno v:
Revista clinica espanola. 213(3)
The cost of control and management of Systemic Lupus Erythematosus (SLE) in Spain is unknown. This study has aimed to describe the healthcare resources associated to control and treatment of LES and its flares and to estimate the associated direct co
Autor:
F Pérez-Alvarez, L León-Ruíz, J M Sabio-Sánchez, Carmen Hidalgo-Tenorio, J Tercedor-Sánchez, Juan Jiménez-Alonso
Publikováno v:
Lupus. 10:824-826
Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect many organs in the body. Skin manifestations are frequent and sometimes vesiculobullous lesions may apper such as in bullous lupus erythematosus. SLE may also be exceptionall
Autor:
J M, Sabio, M, Zamora-Pasadas, J, Jiménez-Jáimez, F, Albadalejo, J, Vargas-Hitos, M D M, Rodríguez del Aguila, C, Hidalgo-Tenorio, M A, Gonzalez-Gay, J, Jimenez-Alonso, J J, Alonso
Publikováno v:
Lupus. 17(9)
The aim of this cross-sectional study was to establish the frequency, phenotype and characteristics of metabolic syndrome (MS), as defined by the Adult Treatment Panel III, in a cohort of patients with systemic lupus erythematosus (SLE) and its possi
Autor:
Norberto Ortego-Centeno, José-Luis Callejas-Rubio, Humbelina Robles-Ortega, María Isabel Peralta-Ramírez, J. M. Sabio-Sánchez, Nuria Navarrete-Navarrete, Juan Jiménez-Alonso, M A Coín, Carmen Hidalgo-Tenorio
Publikováno v:
Psychotherapy and psychosomatics. 79(2)
Background: Chronic stress worsens the quality of life (QOL) of lupus patients by affecting their physical and psychological status. The effectiveness of a cognitive-behavioural intervention in a group of patients with lupus and high levels of daily
Autor:
J, Jiménez-Alonso, J M, Sabio, P L, Carrillo-Alascio, J, Jiménez-Jáimez, N, Ortego-Centeno, E, Jiménez-Jáimez, C, Hidalgo-Tenorio, M, Guzmán-Ubeda, L, Jáimez, R, Cáliz, A, García-Sánchez, M, Gallego, L, Caminal, J L, Callejas-Rubio, R, Cervera, J, Font
Publikováno v:
Revista clinica espanola. 204(11)
A significant proportion of our patients has described to have problems from tolerance to Dolquine, a new presentation of hydroxychloroquine recently marketed in Spain, compared to Plaquenil. The objective was to know the tolerability and the adverse